Autres langues Cocrystal Pharma, Inc.

Actions

COCP

US19188J4094

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,555 ^USD	+2,98 %		+1,64 %	-9,71 %

28/03	Cocrystal Pharma, Inc. annonce ses résultats pour l'année complète clôturée le 31 décembre 2023	CI
04/01	Cocrystal Pharma, Inc. fait le point sur le développement clinique de ses nouveaux candidats antiviraux à large spectre	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	28/03
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	19/03
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	04/01
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	04/01
Top Premarket Gainers	07/12
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	06/12
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	06/12
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	29/11
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	29/11
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	27/11
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	13/11
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	09/11
Cocrystal Pharma : Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 - Form 8-K	31/10/23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	31/10/23
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	28/09/23
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus	28/09/23
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	05/09/23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	14/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cocrystal Pharma, Inc.

Actions

COCP

US19188J4094

Autres langues

Filtres